MMJ BioScience Files Pre Investigational New Drug (IND) Application With FDA For Pharmaceutical Cannabidiol (CBD) derived medicine.

MMJ International Holdings Announces US Patent Filing for Multiple Sclerosis Cannabinoid Treatment
November 27, 2017
MMJ BioScience Announces Partnership with Pharmaceutical Manufacturing Company To Supply Cannabis Medicine For Multiple Sclerosis Study
December 16, 2017

MMJ International Holdings Announces US Patent Filing for Multiple Sclerosis Cannabinoid Treatment

MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, announced today MMJ BioScience’s filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s cannabinoid pharmaceutical compounds for treating and/or preventing symptoms associated with multiple sclerosis (MS).

Dr. Bianca Weinstock-Guttman is a Professor of Neurology at the State University of New York at Buffalo

who serves as Executive Director of the New York State Multiple Sclerosis Consortium will execute the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients. MMJ BioScience’s will be providing new evidence regarding clinical outcomes leading to commercial success in the scientific process of MMJ BioScience’s first pharmaceutical cannabidiol (CBD) derived medicine.

MMJ BioScience’s first clinical trial of cannabis-based medicines involving patients suffering from Multiple Sclerosis and its related forms of severe pain and spasticity will be seeking FDA permission to proceed to undertake a pharmaceutical research study to develop a prescription cannabis-based medicine. MMJ BioScience will commence their Phase 2 clinical trials with the guidance of their clinical research organization Parexel.

Timothy Moynahan Chairman MMJ BioScience stated, “We are very excited about the FDA’s acceptance of our pre IND request, “MMJ BioScience’s discovery of a novel cannabinoid pharmacology through our network of world leading scientists and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.”

Mr. Moynahan added, “Our initiation of the Phase 2 clinical trial programs and the eventual FDA Fast Track Designation for Progressive Multiple Sclerosis signify important steps forward in MMJ BioScience’s ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to MS patients.